Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01630707 · ClinicalTrials.gov registry record · NA
Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack
A NA study, sponsored by TherOx.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01630707 is a NA study that has completed, run by TherOx. The registered enrollment target is 20 participants.
The verdict
NCT01630707, a NA study, has completed, sponsored by TherOx.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the feasibility of the delivery of SuperSaturated Oxygen (SSO2) Therapy for 60 minutes selectively into the left main coronary artery (LMCA). The therapy will be delivered with a commercially available qualified SSO2 delivery catheter used with the TherOx® DownStream® System and Cartridge in the treatment of patients presenting with an anterior acute myocardial infarction (heart attack) ≤ six hours after symptom onset with successful reperfusion (via PCI).
Interventions
- DEVICE SuperSaturated Oxygen (SS02) Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01630707
The ClinicalTrials.gov registry entry for NCT01630707 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TherOx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SuperSaturated Oxygen (SS02) Therapy is the first listed.
NCT01630707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01630707 about?
NCT01630707 is a clinical study titled "Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack". The purpose of this study is to evaluate the feasibility of the delivery of SuperSaturated Oxygen (SSO2) Therapy for 60 minutes selectively into the left main coronary artery (LMCA). The therapy will be delivered with a commercially available qualified SSO2 delivery catheter used with the TherOx® Do...
What is the current status of trial NCT01630707?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2012-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01630707?
The interventions under investigation include: SuperSaturated Oxygen (SS02) Therapy (DEVICE).
Who is sponsoring clinical trial NCT01630707?
This trial is sponsored by TherOx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.